3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
53
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Neoplasms
3
Inflammatory Breast Neoplasms
3
HER2-positive Breast Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Solid Tumor
2
Rectal Neoplasms
2
Neoplasm Metastasis
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Solid Cancers
1
Patient Preference
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Multiple Endocrine Neoplasia
1
Malignant Solid Neoplasm
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
Her2-Positive Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-Positive Early Breast Cancer
1
HER2 Positive Breast Cancer
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Interventions
Gemcitabine
5
Paclitaxel
4
Nivolumab
3
cobimetinib
2
atezolizumab
2
adavosertib
2
Ramucirumab
2
N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide
2
Carboplatin
2
zansecimab
1
tocilizumab
1
tivozanib
1
tislelizumab
1
temsirolimus
1
ridaforolimus
1
plocabulin
1
pexidartinib
1
pevonedistat
1
pembrolizumab
1
pamiparib
1
obinutuzumab
1
necitumumab
1
liposomal doxorubicin
1
lenvatinib
1
glasdegib
1
futuximab
1
demplatin pegraglumer
1
birinapant
1
avelumab
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumors
×
pertuzumab
×
Clear all
No trials found.